Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Refractive Surgery

This article was originally published in Start Up

Executive Summary

For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.

You may also be interested in...



NeuroVision Inc.

NeuroVision Inc. is looking behind the eye to correct vision problems. It is targeting the back of the brain with a Web-based, noninvasive, patient-specific treatment designed to re-wire the neural connections responsible for vision. The company will first target adult amblyopia, and then move on to presbyopia, myopia and other visual disorders.

Medennium Inc.

Phakic intraocular lenses may offer solutions for patients that suffer from high degrees of myopia or hyperopia, Medennium Inc. 's PRL, in phase II clinical trials, is a posterior phakic intraocular lens.

Refractec Inc.

Refractec hopes to offer a low-cost alternative to LASIK, a new, non-laser treatment for the underserved group of patients that suffers from farsightedness or hyperopia.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel